Syndax Pharmaceuticals (1T3) Price & Analysis

4 Followers

1T3 Stock Chart & Stats

€16.68

-€0.49(-2.65%)

At close: Jul 28 4:00 PM EDT

€16.68

-€0.49(-2.65%)

Day’s Range― - ―

52-Week Range€12.00 - €21.66

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€1.40B

Enterprise Value€1.99B

Total Cash (Recent Filing)€547.86M

Total Debt (Recent Filing)€589.38M

Price to Earnings (P/E)―

Beta0.35

Next Earnings

Oct 29, 2026

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.52

Shares Outstanding89,297,090

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)28.16

Price to Sales (P/S)10.56

P/FCF Ratio-5.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€33.16

Price Target Upside98.79% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-1.76

Revenue Forecast (FY)€281.29M

Bulls Say, Bears Say

Bulls Say

Commercial GrowthRapid growth across marketed therapies demonstrates meaningful commercial adoption and expanding revenue scale. Continued increases in Revuforj prescriptions, treated patients, and Niktimvo sales could strengthen operating leverage and improve the company’s ability to fund development internally over time.

Market Access And RetentionBroad formulary access reduces barriers for physicians and patients, while longer treatment duration supports recurring revenue quality. Expanding ordering accounts and sustained therapy indicate that commercial traction is becoming more embedded rather than relying solely on initial launches.

Pipeline DepthA diversified oncology and fibrosis pipeline gives Syndax multiple opportunities to extend its commercial platform beyond current indications. Late-stage studies and new programs create potential durable growth drivers, reducing reliance on any single approved use if clinical execution succeeds.

Bears Say

Persistent UnprofitabilitySubstantial losses and cash outflows show that current commercial growth has not yet translated into self-sustaining operations. Continued dependence on cash reserves or external financing could constrain strategic flexibility and make progress toward profitability sensitive to execution and spending control.

Thin Equity CushionHigh debt relative to the very small equity base leaves limited balance-sheet protection against operating setbacks. This structure can increase refinancing and dilution risk, reduce flexibility for investment, and make future capital allocation more dependent on successful commercialization and liquidity management.

Clinical Execution DependenceA meaningful portion of future growth depends on clinical data and regulatory progress across several programs. Unfavorable results or delays could restrict expansion into larger indications, leaving the company more reliant on existing products while its substantial research spending continues.

Syndax Pharmaceuticals News

Axatilimab’s Emerging IPF and cGVHD Profile Supports Buy Rating on SNDX, With Price Target Unchanged at $57

Syndax Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yigal Nochomovitz from...

7d ago

SNDX

Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks

With the third quarter well underway and most second-quarter earnings now in the rearview mirror, investors are starting...

2M ago

BMEA

SNDX

Syndax price target lowered to $33 from $37 at UBS

UBS analyst David Dai lowered the firm’s price target on Syndax (SNDX) to $33 from $37 and keeps...

2M ago

SNDX

Syndax Pharmaceuticals Earnings Call Signals Strong Momentum

Syndax Pharmaceuticals Inc. (($SNDX)) has held its Q2 earnings call. Read on for the main highlights of the...

2M ago

SNDX

Syndax price target lowered to $40 from $44 at JPMorgan

JPMorgan analyst Anupam Rama lowered the firm’s price target on Syndax (SNDX) to $40 from $44 and keeps...

2M ago

SNDX

Syndax Buy Rating Reaffirmed as Analyst Sees Transitory Demand Weakness, Strong Menin Positioning and Pipeline Catalysts Supporting Unchanged $57 Target

Citi analyst Yigal Nochomovitz maintained a Buy rating on Syndax Pharmaceuticals today and set a price target of...

2M ago

SNDX

Syndax price target lowered to $38 from $40 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Syndax (SNDX) to $38 from $40 and keeps a Buy...

2M ago

SNDX

Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Trajectory and Potential $2B Peak U.S. Sales

TD Cowen analyst Phil Nadeau has maintained their bullish stance on SNDX stock, giving a Buy rating on...

2M ago

SNDX

Syndax reports Q2 EPS (55c), consensus (44c)

Reports Q2 revenue $72.79M, consensus $79.33M. “We delivered another quarter of strong commercial results, with both our medicines...

2M ago

SNDX

SNDX Upcoming Earnings Report: What to Expect?

Syndax Pharmaceuticals Inc. (SNDX) is scheduled to report 2nd quarter earnings on 08/04/2026, after the market closes. Regarding...

2M ago

SNDX

Syndax: Expanding Pipeline and Upcoming Axatilimab IPF Data Support Buy Rating and $29 Price Target Upside

Syndax Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jason Zemansky from...

3M ago

SNDX

Syndax: Strengthening Pipeline and R&D Outlook Support Buy Rating and Unchanged $34 Price Target

Syndax Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Corinne Johnson from...

3M ago

SNDX

Syndax: Advancing Menin Inhibitor and Fibrosis/Oncology Pipeline Supports High-Risk, High-Reward Buy Rating

In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Syndax Pharmaceuticals, with a...

3M ago

SNDX

Syndax: Expanding High-Potential Pipeline and Disciplined Strategy Support Unchanged $40 Price Target and Buy Rating

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Syndax Pharmaceuticals,...

3M ago

SNDX

1T3 FAQ

What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?

Syndax Pharmaceuticals Inc lowest stock price was €12.00 and its highest was €21.66 in the past 12 months.

What is Syndax Pharmaceuticals Inc’s market cap?

Syndax Pharmaceuticals Inc’s market cap is €1.40B.

When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?

Syndax Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 23 days.

How were Syndax Pharmaceuticals Inc’s earnings last quarter?

Syndax Pharmaceuticals Inc released its earnings results on Aug 04, 2026. The company reported -€0.49 earnings per share for the quarter, missing the consensus estimate of -€0.399 by -€0.091.

Is Syndax Pharmaceuticals Inc overvalued?

According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Syndax Pharmaceuticals Inc pay dividends?

Syndax Pharmaceuticals Inc does not currently pay dividends.

What is Syndax Pharmaceuticals Inc’s EPS estimate?

Syndax Pharmaceuticals Inc’s EPS estimate is -0.43.

How many shares outstanding does Syndax Pharmaceuticals Inc have?

Syndax Pharmaceuticals Inc has 89,297,090 shares outstanding.

What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?

Syndax Pharmaceuticals Inc reported an EPS of -€0.49 in its last earnings report, missing expectations of -€0.399. Following the earnings report the stock price went down -7.119%.

Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in DE:1T3

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Syndax Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

18.03%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Syndax Pharmaceuticals (1T3) Earnings & Revenues

Historic Earnings Reports

1T3 Company Deck

1T3 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlights robust commercial momentum (double-digit Revuforj growth, strong Niktimvo adoption, expanding prescriber and payer coverage), meaningful R&D progress with multiple near-term data catalysts, and a strong balance sheet that funds execution toward profitability. Offsetting risks include a quarter-of-quarter dip in new patient starts, limited current penetration in the larger NPM1 population, substantial ongoing expense guidance, and dependence on upcoming data readouts to unlock larger indications. Overall the positives (revenue acceleration, elongating treatment duration, pipeline depth, and cash runway) outweigh the near-term operational and clinical-readout risks.View all DE:1T3 earnings summaries

1T3 Stock 12 Month Forecast

Average Price Target

€33.16

▲(98.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"€11","21":"€21","31":"€31","41":"€41","51":"€51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50.62459218,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€50.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.15762762666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€33.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.09191924,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€23.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21,31,41,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.61,19.226507090769232,21.84301418153846,24.45952127230769,27.076028363076922,29.692535453846155,32.30904254461538,34.92554963538461,37.542056726153845,40.15856381692308,42.77507090769231,45.391577998461536,48.00808508923077,{"y":50.62459218,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.61,17.882894432820514,19.155788865641025,20.42868329846154,21.70157773128205,22.974472164102565,24.24736659692308,25.52026102974359,26.7931554625641,28.066049895384616,29.33894432820513,30.61183876102564,31.884733193846156,{"y":33.15762762666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.61,17.10860917230769,17.607218344615383,18.10582751692308,18.60443668923077,19.10304586153846,19.601655033846153,20.100264206153845,20.598873378461537,21.09748255076923,21.596091723076924,22.094700895384616,22.593310067692308,{"y":23.09191924,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.485,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.725,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.96,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.905,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.505,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.61,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >